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ABSTRACT 
 
Binge-eating disorder is one of the most prevalent illnesses in the U.S. today and 
is characterized by short periods of excessive consumption of palatable food. Our study 
sought to explore the role of the glutamatergic system, one of the key neural pathways 
associated with reward-related learning and motivation, in binge-eating. We trained male 
rats to consume either a highly palatable diet or a standard chow diet within a limited 
time frame (1 hr/day) on a fixed ratio 1 (FR1) schedule of reinforcement. The palatable-
fed rats quickly developed “bingeing” behavior and exhibited compulsive eating and risk-
taking behavior when faced with an aversive environment. We evaluated the effects of 
systemic administration of the uncompetitive NMDA receptor antagonists, ketamine and 
memantine, and found that memantine significantly decreased FR1 responding and 
compulsive eating of palatable food, but not chow, and reduced the difference in risk-
taking behavior between the palatable-fed and chow-fed groups. Site-specific injections 
of memantine into the nucleus accumbens, a key region of reward processing, also 
 v 
decreased responding for food selectively in the bingeing rats. These findings, taken 
together, implicate the glutamatergic system within the mesolimbic reward pathway in 
modulating neuroadaptive mechanisms that lead to the development of binge-eating 
disorder and suggest a potential pharmacological strategy to combat this debilitating 
disease.  
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 1 
INTRODUCTION 
 
One of the most prevalent illnesses in the U.S. today is binge eating disorder. 
Affecting about 3.5% of women and 2% of men (Hudson et al., 2007), this debilitating 
disease has been traditionally thought of as a loss of control (Colles et al., 2008) on the 
part of individuals living in a society where savory food is relatively cheap and easy to 
obtain compared to healthier choices. Eating disorders are gradually being understood to 
be largely complex diseases that result from the interaction between genetic and 
environmental factors (Conn, 2000). Recent literature has suggested dysfunctional 
pathways of the central nervous system (CNS) as the cause for many eating disorders and 
more specifically, pharmacological evidence has shown that binge eating specifically 
may result from neural mechanisms in certain areas of the brain that parallel drug or 
alcohol addiction (Corwin, 2011a). Furthermore, researchers have proposed that a 
“craving” of certain types of junk food may be similar to the craving felt by drug addicts 
and that a return to unhealthy eating habits after a period of dieting could be due to 
withdrawal symptoms originating in the reward centers of the brain (Cottone et al., 2009; 
Avena et al., 2008; Volkow and Wise, 2005).  
Feeding behavior in mammals is largely driven by the hypothalamus, an area of 
the brain involved in many vital functions including sleep, sexual drive, body 
temperature, and the secretion of various hormones (Garcia-Diaz, 2011; Kraly et al., 
1975). The brain area has been thought of as a “hunger center” which responds to a 
reduction in blood glucose levels with increased activity, through the actions of various 
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hormones and neurotransmitters. Because food intake is regulated by so many different 
molecules and pathways, there are potentially multiple targets of intervention when 
dealing with abnormal feeding behavior. The hedonic qualities of highly palatable foods 
have been shown to inhibit the effectiveness of certain hormones (i.e. leptin) to maintain 
satiety (Conn, 2000). Therefore, the rewarding properties of food may be playing a large 
part in the lack of control observed in binge eating behavior. The Merriam-Webster 
dictionary defines reward as a stimulus to an organism following a correct or desired 
response that increases the probability of the response. From a neurobiological 
standpoint, there are 3 components of reward: learning, liking (hedonic component) 
which is represented by hard-wired objective affective reactions across species, and 
wanting (incentive salience), each of which are influenced by selective brain areas. Of 
these, both learning and wanting are influenced by the dopaminergic system (Berridge 
and Robinson, 1998).  
In conditioning processes, dopaminergic nerve cells release dopamine (DA) into 
the ventral striatum when encountering potential reward signaling cues (Schultz, 2008). 
Dopamine’s role in reward function was further explored by discovering that dopamine 
antagonists blocked the rewarding effects of psychomotor drugs (Yokel and Wise, 1975) 
and brain stimulation (Liebman and Butcher, 1974). These results suggest that dopamine 
may contribute to the processing of rewarding stimuli. Dopaminergic fibers and terminals 
in the hypothalamus derive from several sources, including the ventral tegmental area 
(VTA), which projects heavily to the nucleus accumbens (NAcc). This is one of the 
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major pathways of dopamine in the brain and is known as the mesolimbic dopaminergic 
system which is involved in regulating reinforced motivating behavior (Kandel, 2012).  
 
Figure 1: Mesolimbic Dopaminergic System* 
 
*Figure downloaded from University of Colorado, Boulder at 
http://ibgwww.colorado.edu/cadd/a_drug/essays/essay4.htm 
 
The elevation of striatal dopamine levels seen in drug addiction is already well-
documented (Hurd et al., 1989, Pettit and Justice, 1989, Ranaldi et al., 1999). Similar 
results were discovered in the processing of natural rewards such as food (Wise et al., 
1978a, b). More specifically, food reward and food-associated stimuli have been shown 
to increase dopamine levels in the NAcc (Hernandez and Hoebel, 1988, Bassareo and Di 
Chiara, 1999) Although in one study, lesions of VTA neurons resulted in no dopamine 
being released to the NAcc and this did not affect “liking component” of sucrose reward 
(Berridge and Robinson, 1998), dopamine is released intrahypothalamically in both 
medial and lateral areas in conjunction with a meal. Furthermore, starvation in rats, which 
reduces dopamine content in the NAcc, leads to self-stimulation and eating which serves 
to restore dopamine content in the NAcc (Conn, 2000). Clearly, dopaminergic neurons 
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within the mesolimbic system play a role in an animal’s desire and motivation to obtain 
palatable food.  
Operant Conditioning for Food Reward in Rats 
Rats can be trained to lever press for food which is a form of appetitive 
instrumental learning. The animals can learn that food is available from a food dispenser 
in an operant testing chamber outfitted with a lever and maybe another stimulus (i.e. light 
bulb). A downward deflection of the lever is programmed to deliver a food pellet to the 
dispenser. Once rats receive the food in this situation, they actively sniff, bite and attempt 
to manipulate the environmental stimuli associated with the food (Schmidt and Reith, 
2005). Rats tend to return to and manipulate the stimuli associated with the rewarding 
stimulus which in this case is the food. This behavior is continuously reinforced by the 
dispensing of the pellets. The rat’s repeated level pressing is evidence for their 
instrumental learning. Ivan Pavlov and B.F. Skinner have shown that the reinforcing 
efficacy of food reward is due to the ability of the reward to maintain rather than to 
establish instrumental behavior and without reinforcement, there is extinguishing of both 
stimulus associations and response associations (Wise, 2006). 
The Glutamatergic System  
  
The glutamatergic system is involved in many brain areas and has been implicated 
in a variety of physiological processes. The effects of glutamate, the main excitatory 
neurotransmitter in the brain, are mediated by ionotropic and metabotropic receptors 
(Garcia-Diaz, 2011; Schmidt and Reith, 2005). Abnormal regulation of glutamatergic 
transmission underlies many neurological disorders such as schizophrenia and drug 
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addiction, the mechanisms of which may involve interactions between the glutamatergic 
and dopaminergic systems at the striatal level. Extrinsic glutamatergic inputs (prefrontal 
cortex (PFC), amygdala, hippocampus) play a key role in controlling the firing rate and 
pattern of midbrain dopaminergic neurons in the VTA which in turn affects phasic 
dopamine release in the NAcc (Moore et al., 1999). Anatomically, glutamatergic control 
of NAcc activity may be controlled by overlapping axons stemming from the amygdala, 
hippocampus, PFC, and thalamus (Wright and Groenewegen, 1996). The modulation of 
glutamatergic brain structures may exert an alteration in the tight balance of activity 
between glutamate and dopamine transmission to the PFC and NAcc which may be a 
critical factor that underlies psychiatric disease in humans (Schmidt and Reith, 2005).  
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Figure 2: Glutamatergic - Dopaminergic Transmission* 
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Figure F 
 
*Figure amended from Schmidt and Reith, 2005. Abbreviations: NAcc = nucleus 
accumbens, PFC = prefrontal cortex, VTA = ventral tegmental area 
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Dopamine and Glutamate in Reward and Addiction 
The ventral striatum has been shown to be a major component of the brain’s 
reward and motivation processing system (Rilling, 2013). While hunger is thought to 
initiate food-seeking behavior, it is food-related environmental cues that guide this 
behavior (Wise, 2006) which relies on striatal dopamine-dependent associations between 
the cue and the reward. More specifically, dopamine in the NAcc (part of the ventral 
striatum) has been found to attribute motivational value to conditioned stimuli that 
predict rewards (Saunders and Robinson, 2012; Di Chiara, 2002).  
Recent literature suggests that dopamine afferents interact with glutamate 
afferents common to the same cell when reward-related incentive learning and 
subsequent behavior occur (Sutton and Beninger, 1999). Medium-sized spiny neurons 
(MSSN’s), which are GABAergic projection neurons, make up a large majority (~90%) 
of the striatum and NAcc (Gerfen, 2000, Kita and Kitai, 1988). There is significant 
evidence for the interaction between dopamine and NMDA receptors at the MSSN level 
which depends on a number of factors, but in particular the dopamine receptor sub-type 
(Cepeda and Levine, 1998). The spines of these neurons receive glutamatergic inputs 
from cortical neurons and dopamine inputs from mesencephalic neurons (Smith and 
Bolam, 1990). Wickens (1988, 1990) and other researchers (Miller et al., 1990) have 
provided evidence that reward-related learning occurs as a result of dopamine modulation 
of glutamatergic synapses made by cortical afferents on the spines of MSSN’s; 
electrophysiological and neurochemical evidence supports this (Cepeda and Levine, 
1998; Nicola et al., 2000; Reynolds and Wickens, 2000,; Centonze et al., 2001; Reynolds 
 8 
et al., 2001). Dopamine’s modification of the strength of the glutamatergic synapses in 
the NAcc may change the behavior associated with the environmental stimuli that 
activate these synapses. The dopamine release associated with the exposure to rewards 
may produce a consequential change in the release of glutamate which may contribute to 
synaptic strengthening and reinforcement effects. Dopamine stimulation by cocaine, for 
example, enhances a heteroreceptor complex formation between dopamine 2 (D2) 
receptors and NMDA receptor NR2B subunits in the striatum in vivo (Liu, 2006). This 
suggests that dopamine and glutamate pathways, perhaps via D2R-NR2B interactions, 
synergistically modify the behavioral responsiveness to rewards.  
When palatable rewards are encountered, a subset of neocortical cells is activated 
and their synapses in the ventral striatum release glutamate (Sutton and Beninger, 1999; 
Kelley and Berridge, 2002). This leads to NMDA receptor stimulation and an increase in 
calcium concentration in the dendritic spines that receive these synapses (Schmidt and 
Reith, 2005). Increased spine calcium (Ca++) leads to activation of enzymes including 
Ca++-dependent protein kinase (PKC) and calmodulin-dependent protein kinases 
(CaMKs) (Garcia-Diaz, 2011). These enzymes phosphorylate a variety of proteins 
including AMPA receptors, altering their open time and potentially increasing the 
duration of depolarization. As described in further detail below, this process may be 
necessary for some of the molecular signals involved in dopamine-glutamate interactions 
that mediate approach responses when conditioned stimuli associated with reward are 
presented. Therefore, when one approaches palatable food there are synaptic alterations 
within the mesolimbic system that influence one’s subsequent behavior.  
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When reward occurs and dopamine is released, stimulation of dopamine-1 
receptors (D1R) will lead to activation of adenylyl cyclase (AC) and stimulation of cyclic 
adenosine monophosphate (cAMP)-dependent protein kinase A (PKA). PKA 
phosphorylates dopamine and cAMP-regulated phosphoprotein (DARPP-32) which in 
turn inhibits the enzyme protein phosphatase I (PP I) which typically dephosphorylates 
recently phosphorylated proteins in the synaptic spine (i.e. AMPA can remain 
phosphorylated). Activation of PKA leads to activation of cAMP-response-element-
binding-protein (CREB) which affects gene expression (Garcia-Diaz, 2011). CREB 
activation is also affected by NMDA receptor stimulation and increases in Ca++ 
(Konradi et al., 1996; Das et al., 1997) which makes it a good mediator of contiguous 
MSSN activation. Other kinases such as mitogen-activated protein kinase (MAPK) may 
be involved in the stimulation of dopamine or glutamate receptors and/or strengthening of 
their synapses. These signals are thought to be necessary for the acquisition and 
expression of lever pressing for food (Schmidt and Reith, 2005). These results support 
the role of signaling pathways in reward-related learning and the dopamine-glutamate 
interaction model.  
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Figure 3: MSSN Secondary Messenger System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AC = adenylyl cyclase, AMPA = alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor, DA = dopamine, DARPP-32 = dopamine- And cAMP-
regulated phosphoprotein, Gi/Gq/Gs = G-proteins, NMDA = N-methyl-D-aspartate 
receptor, PKA = protein kinase A, PKC = protein kinase C; PP I = protein phosphatase I 
 
 
Pharmacology of NMDA Receptors 
The NMDA receptor is one of the main ionotropic receptors of the glutamatergic 
system and is both ligand-gated and voltage-gated (MacDonald et al., 1982; Flatman et 
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traditionally been explored in addiction-related research, recent literature has implicated 
the NMDA receptor system, due to the prevalence of NMDA receptors across different 
brain regions and their involvement in synaptic plasticity, pain, and epilepsy, among 
other conditions (Ying, 2009). These receptors undergo greater activation with high-
frequency synaptic activation or with concurrent depolarization as their voltage 
dependency is due to a preferential blockade of NMDA receptor channels by magnesium 
(Mg++) ions at negative membrane potentials, which includes the cell’s resting 
membrane potential (Mayer et al., 1984; Nowak et al., 1984). Thus, NMDA receptor 
responses are dependent on the immediately preceding history of the cell (i.e. larger 
responses if the cell is currently depolarized).  
Unlike other ion channels, NMDA receptors are also permeable to Ca++ 
(MacDermott et al., 1986). The influx of Ca++ allows the intracellular second messenger 
system to be activated (Garcia-Diaz, 2011). Although another agonist needs to be present 
(glycine or D-serine) in addition to glutamate in order to achieve channel activation 
(Johnson and Ascher, 1987; Kleckner et al., 1988), the combination of Ca++ permeability 
and voltage dependency allows NMDA receptors to be able to use Ca++ as a trigger for 
experience-dependent plasticity or long-term potentiation (LTP). LTP is defined as high-
frequency stimulation of an afferent input in the brain’s nervous system that leads to 
long-lasting enhancement of the synaptic response when the afferent is tested later with a 
single stimulation (Kandel, 2005). This mechanism is thought to represent a cellular 
mechanism for learning which may be inhibited by NMDA receptor blockade/knockout 
(Morris, 1989).  
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NMDA receptors are multimeric complexes composed of subunits from 3 related 
families: NR1, NR2, and NR3 with the first 2 required for receptor function. Evidence 
suggests that 2 NR1 and 2 NR2 subunits in a single NMDA receptor complex which may 
exist as a tetramer (Laube et al., 1998). The physiological and pharmacological properties 
of NMDA receptors vary with the specific type of NR2 subunit (NR2A-NR2D) present in 
the heteromeric complex (Monyer et al., 1992; Buller et al., 1994; Laurie and Seeburg, 
1994; Williams, 1993).  
Agonists of the NMDA receptor include L-aspartate and L-glutamate. Antagonists 
have same general structural requirements as do agonists with a few key differences. 
Ketamine can block NMDA-receptor action in an uncompetitive manner by binding to a 
site within the open ion channel (Anis et al., 1982) and memantine (Rogoz et al., 2002) is 
a low-affinity uncompetitive NMDA receptor antagonist. Because the NR2 subunit has a 
glutamate-binding site, the 4 different NR2 gene products may each contain a 
pharmacologically-distinct glutamate-binding site, but at present glutamate-site 
antagonists only weakly discriminate b/w the different NR2 subunits (Schmidt and Reith, 
2005).  
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Figure 4: Example Agonists Of The NMDA Receptor* 
 
*Figure downloaded from University College, London at 
http://www.ucl.ac.uk/~smgxt01/frameh.htm?page=glutamat.htm 
 
The role of dopamine and NMDA receptors in instrumental learning in operant 
conditioning tasks has been well-documented. Pharmacological evidence has shown that 
responding for a conditioned reward is also dependent on manipulation of these systems 
(Burns et al., 1994; Kelley and Throne, 1992). Like studies with systemic administration 
of dopamine receptor antagonists, those using intra-NAcc or –medial PFC injections in 
rats have shown that dopamine plays a critical role in the acquisition and expression of 
conditioned approach responses (Schmidt and Reith, 2005; Parkinson et al., 2002). Intra-
NAcc injections of dopamine D1-like receptor antagonist impaired acquisition of operant 
response in the lever pressing paradigm (Smith-Roe and Kelley, 2000) and it also 
decreased locomotor activity and increased the average duration of feeding bouts in a 15-
min test but did not affect the total amount of food eaten. Interestingly, the authors could 
not rule out that the effect of the injection into NAcc on lever press acquisition was 
related to its motor effects. The same authors injected the NMDA receptor antagonist R-
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2-amino-5-phosphonopentanoate (AP5) into the NAcc core and shell and although 
operant learning was impaired (similar to above), locomotor activity and feeding was not 
significantly affected (Kelley et al., 1997). Similarly, when the noncompetitive NMDA 
receptor antagonist ketamine was injected systemically, it impaired lever press 
acquisition in a dose-dependent manner (Freed and Wyatt, 1981).  
Figure 5: Common NMDA Receptor Antagonists* 
 
*Figure downloaded from Royal Society of Chemistry at 
http://pubs.rsc.org/en/content/articlehtml/2002/P1/B111540P 
 
Pharmacology of Memantine and Ketamine 
A variety of antagonists of the NMDA receptor have been described and these are 
distinct because of their different mechanisms of action towards the receptor. 
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Competitive antagonists compete with glutamate to bind to the glutamate binding site or 
compete with glycine to bind to the glycine binding site, respectively and are reversible 
in their binding. AP5 is an example of a competitive NMDA receptor antagonist 
(Schmidt and Reith, 2005). Antagonists are said to be uncompetitive when they bind to 
internal sites inside of an open receptor pore which means that an agonist must have 
already acted on the receptor to open it for the uncompetitive antagonist to find its target. 
Both memantine and ketamine are uncompetitive NMDA receptor antagonists (Cottone et 
al., 2013) which block current flow through these receptors by entering the channel and 
preventing cation influx and subsequent depolarization (Johnson and Kotermanski, 
2006). The half maximal inhibitory concentration (IC50) of ketamine is 0.43 μM at the 
NMDA receptor in the rat brain (Parsons et al., 1996). Ketamine also interacts with the 
phenylcyclidine (PCP) binding site of the NMDA receptor (Smith et al., 1987) which 
incidentally happens when the ion channel is open. The half maximal inhibitory 
concentration (IC50) of ketamine is 6.6 μM at the PCP binding site of the NMDA 
receptor (Volle et al., 1982). Ketamine also exhibits affinity for opiate and muscarinic 
receptors (Hirota and Lambert, 1996). The IC50 values at these receptors are 1.32 μM 
and 5.7 μM (Durieux, 1995), respectively. However, as ketamine has many targets for 
pharmacological action, it also expresses many behavioral side-effects including 
hypertension, nausea, hypersalivation, dizziness, and psychomotor retardation (Quibell et 
al., 2011). Some of these side-effects, such as euphoria and hallucinatory visions, have 
led to the abuse of this drug by recreational users (Moore and Measham, 2006). The risk 
of potentially dangerous side-effects makes this drug unlikely to ever seriously be 
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considered in treating binge-eating disorder in a clinical setting, but its effects on binge-
like eating behavior in a pre-clinical setting could be useful in learning more about the 
glutamatergic system involvement in the disease.  
Figure 6: Structure Of Ketamine 
 
*Figure downloaded from National Library of Medicine at 
http://toxnet.nlm.nih.gov 
 
Other NMDA receptor antagonists are also reported to have side-effects (Palmer, 
2001) in a clinical setting. This may be due to the fact that receptor blocking ability of an 
antagonist at the NMDA receptor is inversely related to antagonist potency. For example, 
amantadine has relatively fast blocking kinetics, but a low potency (IC50 = 18.6 μM) 
while dizocilpine has slow kinetics but a high potency (IC50 value = 0.12 μM) (Parsons 
et al., 1996). The uncompetitive NMDA receptor antagonist memantine has been reported 
to have fewer side-effects (Lipton, 2004) and this may be due to its relatively 
intermediate properties compared to other antagonists. It has an IC50 value of 1 μM at 
the NMDA receptor at -60 mV (Chen and Lipton, 1997).  
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Figure 7a: Structure Of Memantine; Figure 7b: NMDA Receptor 
 
*Figure taken from Johnson and Kotermanski, 2006 
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Existing literature states memantine binds at or near the Mg
2+
 site within the 
NMDA receptor ion channel (Lipton, 1993; Chen and Lipton, 1997; Chen et al., 1992; 
Chen et al., 1998). 
 
During normal synaptic activity, the ion channels stay open for an 
average of only several milliseconds. At resting membrane potential (-70 mV), the 
average open time for these channels is between 0.10 and 0.20 ms (Kleckner and Pallotta, 
1995).  With a relatively high unblocking rate constant (0.44 s
-1
) which is independent of 
drug concentration (Chen and Lipton, 1997), memantine tends not to accumulate inside 
of the channel which is responsible for many of the side-effects seen with other NMDA 
receptor antagonists as excessive blocking may impair both pathological and 
physiological neural transmission. Memantine seems to maintain normal synaptic 
transmission, preserve LTP, and maintain physiological function on behavioral tests such 
as the Morris water maze (Chen et al., 1998). Consequently, memantine is a very 
effective NMDA channel blocker in a clinical sense due to its reduction of excessive 
excitatory activity without significantly affecting normal physiological function. In 
addition to its impact on NMDA receptors, memantine has other targets in the CNS. 
Memantine has been found to affect dopamine uptake (IC50 = 210 μM), serotonin uptake 
(IC50 =  μM), nicotine acetylcholine receptors (IC50 = 10 μM), and serotonin receptors 
(IC50 = 50 μM), among other targets (Danysz et al., 1997; Brau et al., 2001). These 
various action sites of memantine may affect behavior to a degree at high concentrations, 
but these have not been significant enough to affect its use in clinical setting in situations 
of NMDA receptor over-stimulation.  
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NMDA receptor antagonism: a novel target for the treatment of binge disorder 
The effects of NMDA receptor antagonism on binge-eating like behavior have 
been explored to a degree. In studies with both animals and humans, uncompetitive 
NMDA receptor antagonists like memantine have affected food intake. Popik et al. 
(2010) determined that chronic memantine administration reduced palatable food 
consumption in a limited access procedure (Corwin, 1998). In this model, rats had access 
to a highly palatable lard-based diet inside of their homes cages. In a study with five 
obese women, NMDA receptor antagonism by memantine was found to decrease appetite 
within a few hours and body weight within a few days. These findings indicate that 
NMDA receptor antagonism shows promise as a potential new therapeutic target for the 
treatment of binge-eating disorder. 
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OBJECTIVES 
 
The lack of pharmacotherapies for binge eating disorder persists despite growing 
understanding of the various systems involved, although there are treatment proposals 
(Cottone et al., 2007, Blasio et al., 2013) currently on the table. The mesolimbic 
dopaminergic system is widely acknowledged as being involved in regulating reinforcing 
effects of reward (Bisaga et al., 1998) such as palatable foods. Reward-related learning 
and subsequent behavior may be mediated by the dopamine-glutamate interactions within 
this pathway. We sought to explore the role of the mesolimbic system in modulating 
palatable food intake by focusing on reinforcement in reward-related behavior.  
The overall goal of this thesis was to determine whether uncompetitive NMDA 
receptor antagonism is a tenable target for the treatment of binge eating disorder. We 
tested this hypothesis, mimicking both the consummatory and motivational aspects of 
binge eating disorder, using a newly developed operant model of binge-like eating where 
rats self-administer a highly palatable diet under limited access conditions (1 hour/day) 
(Cottone et al, 2012; Blasio et al., 2013) and using a compulsive eating/risk-taking 
paradigm. 
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The specific objectives are to: 
1) Determine whether acute systemic administration of the uncompetitive NMDA 
receptor antagonists memantine and ketamine, would decrease binge-like eating 
behavior, using our novel operant binge model in rats. .  
2) Investigate whether systemic uncompetitive NMDA receptor antagonism would 
decrease palatable food-driven compulsive feeding and risk-taking behavior in the 
rat.  
3) Determine whether intra-NAcc shell uncompetitive NMDA receptor antagonism 
would decrease binge-like eating behavior in the rat.  
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METHODS 
 
Animals 
Male wistar rats (experiment 1, n = 17-18; experiment 2, n = 10; experiment 3, n 
= 39 experiment 4, n = 16  45 days old upon arrival (Charles River, Wilmington, MA) 
were housed in wire-topped, plastic cages (27 x 48 x 20 cm
3
) in a 12:12 hour reverse light 
cycle (lights off at 11 AM EST daily), in a humidity (30-70%) and temperature-
controlled (20-26
o
C) vivarium. Rats were group-housed in the abovementioned cages and 
had access to corn-based chow (Harlan Teklad LM-485 Diet 7012 (65% (kcal) 
carbohydrate, 13% fat, 21% protein, 341 cal/100 g); Harlan, Indianapolis, IN) and water 
ad libitum. Procedures adhered to the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (revised 2011, 8
th
 edition) and the Principles of Laboratory 
Animal Care (http://www.nap.edu/readingroom/bookslabrats), and were approved by 
Boston University Institutional Animal Care and Use Committee (IACUC).  
 
Drugs 
Memantine hydrochloride (1,3-dimethyl-5-aminoadamantane hydrochloride, MW 
= 215.77 g/mol) was purchased from Acros Organics (Geel, Belgium). For systemic 
studies, memantine was dissolved in isotonic filtered saline (0.9%) on the day of the test 
before use. Memantine was administered intraperitoneally (0, 1.25, 2.5, 5, and 10 mg/kg, 
1 mL/kg, I.P.) 30 min before operant binge sessions. Memantine was also dissolved in 
isotonic filtered saline (0.9%) immediately prior to infusion directly into the NAcc (5, 20 
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and 40 µg/µL, 0.5 µL per hemisphere) before behavioral testing. Doses, injection 
volume, suitability of the vehicle, and pretreatment times were based on previously 
published reports (Réus et al., 2012; Cottone et al., 2012; Idrus et al., 2011; Rassnick et 
al., 1992; Bespalov et al., 2000).  
 Ketamine hydrochloride ((±)-2-(2-chlorophenyl)-2-(methylamino) cyclohexanone 
hydrochloride; MW = 274.19 g/mol) was purchased from Sigma-Aldrich (St. Louis, 
MO). Ketamine was freshly dissolved in isotonic filtered saline (0.9%) on the day of the 
test for immediate use. Ketamine was administered (0, 5, 10, and 20 mg/kg, 1 ml/kg, I.P.) 
30 min before the session. Doses, injection volume, suitability of the vehicle, and 
pretreatment times were based on previously published reports (Garcia et al., 2009; 
Cottone et al., 2012). 
  All drugs described were injected using a within-subject Latin square design, 
unless otherwise stated. 
 
Operant binge-like eating procedure 
Operant test chambers, described in detail in Blasio et al. (2012) and Cottone et 
al. (2012), were used for self-administration of food and water by the animals.    
Operant chamber training: As previously described (Cottone et al., 2012), 
animals were trained on the operant model of binge eating. Rats were fed the standard 
Harlan Teklad diet in their home cage. After a period of acclimation in the vivarium, food 
was replaced with an AIN-76A-based diet, hereafter referred to as ‘Chow A/I’ (5TUM 
diet formulated as 4–5 g extruded pellets, 65.5% (kcal) carbohydrate, 10.4% fat, 24.1% 
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protein, 330 cal/100 g; TestDiet, Richmond, IN). Rats were trained to self-administer for 
food (45-mg precision food pellets (Chow A/I)) and water (100 μL) under a fixed ratio 1 
(FR1) schedule of reinforcement (Cottone et al., 2009) inside of the operant chambers. 
45-mg precision pellets, which are identical in composition to the home cage Chow A/I 
extruded diet, were delivered in order to ensure that homeostatic, not hedonic, needs were 
driving the chow-fed rats’ food intake (Cottone et al., 2009; Cottone et al., 2008). The 
one-hour long daily sessions were performed before the dark cycle onset (11 AM). A 
light cue (0.3 sec), located above the nose-poke hole, was paired with successful nose-
poke and pellet delivery.  
Figure 8: Operant Conditioning Box 
  
*Figure downloaded from Med Associates Inc. at http://www.med-
associates.com/products-page/self-administration/self-administration-chambers-for-
rat/standard-modular-operant-test-chamber-with-modified-top-for-rat/ 
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Fixed ratio schedule testing: After stable baseline performances were achieved in 
the 1 hour FR1 schedule self-administration sessions, the testing procedure was initiated 
where the animals were matched for body weight, daily food intake, feed efficiency, and 
water and food responding in the self-administration. Half of the rats in each cohort were 
assigned to a “Chow” control group, in which the operant boxes dispensed the same 45-
mg chow pellets offered in the training phase. The remaining rats were assigned to a 
“Palatable” group, which instead received a nutritionally complete, chocolate-flavored, 
high sucrose (50% kcal) AIN-76A-based diet, comparable in macronutrient composition 
and energy density to the chow diet (chocolate-flavored Formula 5TUL: 66.7% [kcal] 
carbohydrate, 12.7% fat, 20.6% protein, metabolizable energy 344 cal/100g; formulated 
as 45 mg precision food pellets; TestDiet, Richmond, IN).  It has been determined that 
this chocolate-flavored diet is strongly preferred by all rats (Cottone et al., 2008). The 
one-hour long daily sessions were performed before the dark cycle onset. 
 
Experimental Procedures  
Experiment 1: Administration of the selective uncompetitive NMDA receptor 
antagonists memantine and ketamine on operant binge-like eating 
 Rats (n = 19) were trained for the FR1 binge-like eating procedure and, following 
food intake stabilization and division into either the “Chow” control or “Palatable” 
group, were pretreated with memantine (0, 1.25, 2.5, 5, and 10 mg/kg, I.P.) using a 
within-subject Latin square design and run on the FR1 schedule of pellet reinforcement. 
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Following a short washout period (5 days) and the re-establishment of the baseline in the 
binge-like eating, the rats were then treated with ketamine (0, 5, 10, and 20 mg/kg, I.P.) 
and tested again in the FR1 binge-like eating procedure. Rats received drug doses on 
alternating days within the Latin square design. 
Experiment 2: Effects of the selective NMDA antagonist memantine on high rate of 
responding for Chow A/I induced by food restriction 
A separate cohort of rats (n = 10) was trained to acquire operant self-
administration for Chow A/I diet (see “Training” in “Operant model of binge-like eating” 
paragraph) but after depriving them of this diet in their home cages after the third day of 
arrival until the conclusion of the experiment (2 weeks later). For the first 3 days, rats had 
food and water ad libitum in their home cages as the rats described above. To increase the 
rate of responding for Chow A/I during the operant self-administration sessions (Cottone 
et al., 2012), rats were food restricted in their home cages (~70% of a rat daily intake as 
determined by the amount of home cage intake + food self-administered).  More 
specifically, the amount of food each rat received in his home cage was calculated based 
on averaging the amount of food in grams that was consumed in the 1-hour long operant 
conditioning procedure by each rat and then subtracting that amount by 20 grams, so that 
each rat received an average of 20 grams of chow consumed per day. This diet regime 
was continued for 3 days, when the total amount the rats would have access to on a daily 
basis was reduced to 19 grams for 2 days, then 18 grams for 1 day, and finally 17 grams 
each day until the conclusion of the food deprivation. To assess the effects of memantine 
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(0 and 10 mg/kg, I.P.) on high rate of responding for the Chow A/I diet in food-restricted 
rats, animals were injected using a within-subject Latin square design.  
Experiment 3: Effects of the systemic memantine on risk-taking behavior and 
compulsive-like eating 
A cohort of rats trained in the operant binge-like eating model (n = 39) were 
administered memantine to test its effects in a 10-min light/dark conflict test as 
previously described in Cottone et al. (2012) and Teegarden and Bale (2007). A pre-
weighed amount (150 g) of the same food received during self-administration (45-mg 
Chow A/I pellets for the chow-fed rats or 45-mg chocolate pellets for palatable-fed rats) 
was positioned in the center of the light compartment. The light/dark rectangular box 
(50×100×35 cm) consists of an the aversive light compartment (50×70×35 cm), 
illuminated by a 60 lux light and a dark side (50×30×35 cm) that is completely covered 
(~0 lux of light as measured using a lux meter).  
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Figure 9: Compulsive Eating Diagram 
 
On the test day, 24 hours after the prior day’s binge-like eating procedure which 
represents a period of “withdrawal” from the chocolate for the palatable-fed group, rats 
were pretreated with memantine (0 and 2.5 mg/kg, I.P.) 30 min before being placed into 
the light compartment for 10 min. The animals were placed in the light compartment 
facing both the food cup and an open doorway that allowed rats to move freely between 
the two compartments (Dore et al., 2013). The amount of food eaten during the test was 
measured in addition to how much time was spent in each of the two compartments. The 
constructs of “risk-taking behavior” and “compulsive-like eating” were operationalized 
by the following variables: food eaten and time spent in the light. Because of rats’ innate 
fear for bright, aversive environments, the time spent exploring the light compartment of 
the light/dark box under normal, control conditions is minimal (Cottone et al., 2012). The 
more time spent by the rat in the light compartment, as compared to vehicle-treated diet 
appropriate controls, results most likely from the presence of the highly palatable diet and 
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is considered a form of “risk-taking behavior” in this animal model (Dore et al, 2013; 
Teegarden and Bale, 2007). Since eating behavior is typically reduced when a rat faces 
adverse circumstances under normal conditions, an increase in food intake in spite of 
what the rats perceived as aversive conditions, as compared to control conditions, was 
considered a form of “compulsive-like eating” in this animal model (Cottone et al., 2012; 
Belin et al., 2008; Davis et al., 2010; Hopf et al., 2010; Johnson and Kenny, 2010). Water 
was not available during the 10 min test and each compartment was cleaned with water 
and a paper towel after each individual 10 min test session.  
Experiment 4: Effect of Intra-NAcc memantine on operant binge-like eating 
Intracranial surgeries: Following stabilization of intake in the operant sessions, 
rats (n = 20) were implanted with a cannula into the intra-nucleus accumbens shell. 
Stereotaxic surgeries were performed as previously described (Cottone et al., 2007; 
Iemolo et al., 2012; Sabino et al., 2007). Briefly, rats were anaesthetised using a 3-5% 
isoflurane/O2 mix. The interaural bar was set at flat skull (dorsal/ventral: bregma = 
lambda). Stereotaxic co-ordinates for the guide cannula placement were corrected from 
the middle of the Bregma by the following calculation: A/P +1.06 mm, M/L ± 0.75 mm, 
D/V -5.5 mm; these coordinates were based on the atlas of Paxinos & Watson (Paxinos, 
1986). Small burr holes were used to open the surface of the skull at the corrected co-
ordinates using a dremel drill. Four additional small burr holes were opened surrounding 
the cannula site for jeweller’s screws (Plastics One, Inc., Roanoke, VA, USA). These 
screws, used in conjunction with dental cement (Henry Schein 
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Inc., Melville, New York, USA), secure the cannula to the skull. Once the cement was 
dry, the retractors were removed and the wound was sutured to avoid infection. A 
stainless steel dummy stylet (Plastics One, Inc., Roanoke, VA, USA) maintained patency. 
After surgery, rats were allowed to recover from the surgical procedure for 1 week before 
the experimental procedure began.  
Microinfusion procedure. Rats were habituated to the microinfusion procedure 
with the insertion of sham injectors (0.75 mm) for 3 days. The dummy stylet was 
removed from the guide cannula and the sham injector was inserted in its place for 2 min 
before the dummy and its cap were replaced and the subsequent start of the binge session. 
For the microinfusion of memantine and saline vehicle, the dummy stylet was removed 
from the cannula and a stainless steel injector projecting 1.5 mm for NAcc shell beyond 
the tip of the cannula was inserted in its place right before infusion began. PE 20 tubing 
was used to connect the injector to a Hamilton microsyringe driven by a microinfusion 
pump (Kd Scientifics/Biological Instruments, Holliston, MA, USA). Rat received a 1 μL 
(0.5μL per hemisphere) volume over 2 min. This was followed by leaving the injectors in 
situ for 1 min to ensure the volume of the solution was dispensed completely. The order 
of drug treatments was given using a full Latin square design, with treatment-free test 
days in between injection days, which allowed food intake to stabilize to baseline levels. 
Memantine was also dissolved in isotonic filtered saline (0.9%) for infusion directly into 
the NAcc (5, 20 and 40 µg/ µL, 0.5 µL per hemisphere) and was infused immediately 
before testing in the FR1 binge-like eating procedure. Cannula placement was verified by 
post-mortem Indian ink infusion at the conclusion of all testing. 
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Statistical Analysis 
Binge eating behavioral data were analyzed using a 2-way repeated measures 
ANOVA (Dose as a within-subject factor, and Diet as a between-subjects factor). Data 
generated by the food restricted rats in the operant binge paradigm were analyzed using 
2-tailed paired Student t-test (Dose as a within-subject factor).  The compulsive 
eating/risk taking data was analyzed using a 2-way ANOVA (Memantine treatment as a 
within-subject factor and Diet as a between-subjects factor). Follow up pair-wise 
comparisons were analyzed using the LSD (Fisher’s least significant difference) post-hoc 
test where appropriate. 
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RESULTS 
 
Experiment 1: Effect of systemic administration of   NMDA receptor antagonist 
memantine and ketamine on operant binge-like eating. 
Memantine treatment 
Systemic memantine treatment reduced  the binge-like eating of Palatable rats in 
the operant FR1 food intake task. A two-way repeated measures ANOVA indicated a 
main effect [Diet F(1, 15) = 63.721; p<0.001); [Dose F(4,60) =5.933; p< 0.0001] and an 
interaction between the two factors [F(1,15) =8.053; p< 0.05]. Palatable rats had 
significantly higher rates of response and food intake compared to Chow controls 
(p<0.01, see Figure 10a). Systemic administration of memantine dose-dependently 
reduced FR1 responding in Palatable groups, without altering intake in the Chow group. 
LSD post hoc analysis revealed that although the 1.25 mg/kg dose was ineffective, all of 
the other doses significantly reduced binge-like eating (2.5 mg p < 0.01; 5 mg p < 0.01, 
10 mg p < 0.001) when compared to vehicle-treated Palatable rats. Water intake was not 
affected by treatment in either Chow or Palatable groups (Figure 10b); No main effect or 
interaction of Factors [Dose F(4,60) =1.134; Diet F(1,15) = 0.108;  Interaction of factors F(1, 
15) = 0.149 n.s.).  
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Figure 10: Effects Of Systemic Administration Of Memantine 
 
 
Ketamine treatment 
A two-way repeated measures ANOVA indicated a main effect [Diet (F (1,16) 
=56.498; p<0.001], but not with dose or interaction [Dose F(3,48) =1.399, n.s.; Interaction 
of factors [F(1,16) F=0.488, n.s.]. Palatable rats had significantly higher rate of responses 
and intake of food intake compared to Chow fed controls (Figure 11a, p < 0.001). 
Ketamine treatment did not alter water intake [Dose: F(3,48) =1.191; Diet: F(1,16) = 0.005; 
interaction F (1,16) = 2.847 n.s.). 
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Figure 11: Effects Of Systemic Administration Of Ketamine 
 
Experiment 2: Effect of systemic administration of memantine on high rate of 
responding for Chow A/I induced by food restriction. 
As shown in  Figure 12, systemic memantine did not significantly reduce the high 
rate of responding for Chow A/I in the operant FR1 food intake task in food restricted 
rats [t(9) = 1.890, 0.236].    
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Figure 12: Effects Of Memantine On Food Deprived Rats 
 
Experiment 3: Effect of systemic memantine on risk-taking behavior and 
compulsive-like eating.  
 
Memantine reduced the compulsive eating of Palatable rats in the risk-
taking/compulsive eating test. As shown in Figure 13a, the Palatable group showed 
compulsive-eating behavior, consuming more food compared to the Chow rats over the 
10-min exposure to the test [Diet F(1,34) =10.81, p<0.005], even though the food was 
placed in a bright, aversive compartment.  The pre-treatment with memantine (2.5 mg/kg, 
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I.P.) was able to block the compulsive eating behavior, dramatically reducing the amount 
of food eaten by Palatable rats [Treatment: F(1,34) =9.99, p<0.005; Diet × Treatment: 
F(1,34) =10.34, p<0.005]. Post-hoc comparisons showed vehicle-treated Palatable rats 
consumed significantly more food than vehicle-treated Chow rats [p<0.001]. Memantine-
treated Palatable group ate significantly less food than the vehicle-treated Palatable ones 
[p<0.001].  
Interestingly, the Palatable rats showed risk-taking behavior when placed in the 
bright compartment with food available, spending more time in this aversive 
compartment compared to the control Chow rats. [Diet F(1,31) =4.83, p<0.05]. Although 
memantine seemed to exert a differential effect in animals with different Diet history 
[Treatment: F(1,31) =0.04, NS; Diet × Treatment: F(1,31) =5.39, p<0.05], the post-hoc 
analysis revealed no statistically significant difference in the time spent in the light 
compartment between memantine-treated and vehicle-treated animals of both groups. 
Post-hoc comparisons pointed out that vehicle-treated Palatable rats spent significantly 
more time in the aversive environment compared to vehicle-treated Chow animals 
(p<0.01) as seen in Figure 13b.  Memantine-treated Palatable rats did spend less time in 
the light compared to vehicle-treated Palatable rats but this was not significant (p=0.14). 
The difference between the Chow and Palatable groups seen with vehicle treatment did 
not extend to memantine treatment where the time spent between the 2 groups was nearly 
the same (p=0.93).   
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Figure 13: Effects Of Memantine On Compulsive-Like Eating And Risk-Taking 
Behavior 
 
Experiment 4: Effect of Intra-Nacc memantine on operant binge-like eating. 
A two-way repeated measures ANOVA indicated main effects of both factors 
[Diet F(1,14) = 37.620; p<0.0001]; [Dose F(3,42) =6.892; p< 0.01] and an interaction 
between the two [F(1,14) =5.969; p < 0.05]. Palatable rats had significantly higher rates of 
response and food intake compared to Chow controls (Figure 14a, p < 0.001). LSD post-
hoc analysis revealed vehicle-treated Palatable rats ate significantly more during the 
binge session compared to vehicle-treated Chow rats (p < 0.001). Intra-Nacc 
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administration of memantine dose-dependently reduced FR1 responding in Palatable 
groups, without altering intake in the Chow group. Post hoc analysis revealed 20 ug/uL 
and (p < 0.05) and 40 ug/uL (p < 0.01) significantly reduced binge-like eating when 
compared to vehicle-treated Palatable rats. Water intake was not affected by treatment in 
either Chow or Palatable groups (Figure/Table; No effect of Dose F(3,42) =0.163; Diet 
F(1,14) = 0.170 or interaction of factors F(1, 14) = 0.82 n.s.).  
Figure 14: Effects of Intra-NAcc Administration of Memantine  
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DISCUSSION 
 
 
 This is the novel study investigating the effects of memantine on binge-like 
eating. Here, we have demonstrated that systemic administration of an uncompetitive 
NMDA antagonist, memantine, reduced the excessive palatable food intake in the 1-hr 
operant sessions, whilst ketamine (uncompetitive NMDA receptor antagonist) had no 
effect. It was shown that this decrease was selective for Palatable rats as memantine did 
not significantly reduce responding for regular, less palatable chow in highly motivated, 
food deprived rats. Bingeing rats (those exposed to palatable food) also exhibited 
compulsive eating behavior as measured by increased intake of the more palatable food 
located in a lighted, aversive compartment compared to their chow-fed controls. These 
rats also express increased risk-taking behavior by spending more time in the lighted, 
aversive compartment. Systemic administration of memantine decreased the compulsive 
eating of palatable food by the bingeing rats. Memantine-treated Palatable rats did spend 
less time in an aversive compartment compared to their vehicle-treated Palatable 
counterparts. Memantine-treated Palatable rats were also found to spend a similar 
amount of time compared to vehicle-treated Chow rats in an aversive setting. Intra-NAcc 
memantine administration both selectively and dose-dependently reduced palatable food 
intake compared to vehicle-treated palatable-fed controls. We suggest that memantine 
decreases food intake as function of the reinforcing efficacy of food. 
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This study was the first to determine the effects of the uncompetitive NMDA 
receptor antagonists memantine and ketamine on a operant conditioning model of binge 
food intake. We showed that systemic memantine but not ketamine administration dose-
dependently decreased palatable food consumption without affecting water intake in 
bingeing rats. Other studies have employed the use of NMDA receptor antagonists on 
food intake. Chronic systemic administration of memantine decreased consumption of 
palatable lard-based food (Popik et al., 2010) in a non-operant, limited access procedure 
(Corwin et al., 1998. In a similar study done in baboons, intramuscular administration of 
memantine was found to decrease palatable food (“candy”) consumption. Experimenters 
gave baboons an irregular and limited access to candy which resulted in a level of 
consumption during a single meal that was comparable to a single day’s consumption of 
standard food pellets (Bisaga et al., 2008). Limited access to palatable food resulted in a 
“binge-type” pattern of consumption in both rats and baboons. Reduction of palatable 
consumption but not that of standard chow by memantine strengthens the role of 
glutamatergic neurotransmission in altering the reinforcing effects of palatable foods.  
In the non-bingeing, control group, memantine did not alter chow pellet 
consumption or water intake. Memantine did not significantly decrease lever pressing for 
chow pellets in rats that were food deprived, compared to vehicle-treated rats (I.P.). 
Using the highest systemic dose (10 mg/kg) we did not observe a change in the rate of 
responding for chow food thus, we could rule out the alternative hypothesis that the 
suppressive effect of memantine on binge-like eating was due to a reduction in 
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responding. These findings indicate that the effects of memantine on binge-like eating are 
not due to cognitive or motor impairment.  
The role of other NMDA receptor antagonists in feeding behavior has also been 
explored. Pierce et al. (1997) reported that dizocilpine (uncompetitive NMDA receptor 
antagonist, I.P.) had no effect on responding for food in rats. However, this study did not 
distinguish responses for a standard food pellet that maintains the homeostatic state and a 
much more palatable pellet which carries a strong hedonic component (Cottone et al., 
2012). The model we used mimics the behavioral adaptation seen in humans in the 
development of a pathological state when exposed to highly palatable food. Systemic 
administration of dizocilpine increases intake of highly palatable food (vanilla wafers) in 
rats without affecting regular chow intake or water intake in satiated rats (Burns and 
Ritter, 1997). However, there are several few procedural differences between the 
previous study and ours: In the Burns study, researchers used a free-feeding model of 
palatable food intake which differed from our operant conditioning model of food intake, 
and rats were satiated, being exposed to standard chow before palatable food 
presentation. While this evidence strengthens the role of NMDA receptors in the control 
of food intake, the neuroanatomical site of action for this mechanism was not determined. 
As NMDA receptors are prevalent throughout the brain, the explanation for an increase in 
food intake may be due to increased positive orosensory qualities of food or an 
interference of the termination of satiety signals (Burns and Ritter, 1997) both of which 
are governed by the hypothalamus. Independent of these effects is the rewarding 
properties of and subsequent behavioral reactions towards palatable food which may be 
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governed by the mesolimbic dopaminergic pathway. This system, known to be involved 
in processing of other rewarding stimuli such as drugs of abuse, also possess a dense 
concentration of NMDA receptors that may be involved in the regulation of palatable 
food intake (Schmidt and Reith, 2005).  
Glutamatergic involvement in food-reinforced behavior has been well-
documented. While studies have demonstrated that glutamate receptors in the 
dopaminergic and hypothalamic systems may mediate feeding behavior (Maldonado-
Irizarry et al., 1995), the administration of ionotropic receptor agonists and antagonists 
has yielded contradictory results in food intake behavior (Burns and Ritter, 1997; Stanley 
et al., 1993; Echo et al., 2001; Khan et al., 2004; Stanley et al., 1996; Ninan and 
Kulkarni, 1998). Mixed effects have also been seen with glutamate metabotropic receptor 
ligands. Intracerebroventricular administration (I.C.V.) of metabotropic glutamate 
receptor 5 (mGluR5) agonists dose-dependently increase food intake in rats while 
antagonists decrease it (Ploj et al., 2010). The mGluR2/3 agonist LY 379268 (I.P.), which 
decreases glutamate release, does not alter sucrose self-administration in rats (Bossert et 
al., 2006). As mentioned above, these results could be due to the fact that glutamatergic 
drugs may reach several targets in the brain which all regulate different food-related 
behaviors ranging from energy-level regulation to compulsive behavior. The plethora of 
glutamate receptor subtypes makes this conclusion even more likely. Glutamate clearly 
plays a role in the regulation of feeding behavior, but either increasing or decreasing 
glutamate neurotransmission in general in the brain has led to inconsistent results. The 
NAcc, which receives input from neocortical, hippocampal, and thalamic regions, may be 
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involved in integrating all this information to initiate feeding behavior (Kirkham and 
Cooper, 2011). The sensory properties of palatable food may disrupt normal 
communication in the brain which inhibits eating when homeostatic needs are met. 
Repeated exposure to palatable food may somehow alter normal transmission in the 
NAcc, particularly within the glutamate system, leading to abnormal food intake.  We 
propose that NMDA receptor antagonists may reduce the reinforcing properties of highly 
palatable food in a manner analogous to the ability of NMDA receptor antagonists to 
modulate self-administration of other rewarding agents such as cocaine and alcohol 
(Holter et al., 2000) by normalizing glutamate neurotransmission. 
One of the most well-known drugs of abuse is cocaine, a potent alkaloid known to 
directly affect mesolimbic dopamine neurotransmission (Fattore et al., 2009). Pierce et al. 
(1997) determined that relatively low doses (0.2-0.3 mg/kg, I.P.) of dizocilpine enhanced 
cocaine self-administration in rats without affecting mesolimbic dopamine transmission. 
This is inconsistent with similar studies where dizocilpine (I.P.) was found to augment 
cocaine reward (Ranaldi et al., 1996) and another where dizocilpine (I.P.) failed to shift 
the dose-response curve for cocaine self-administration (Schenk et al., 1993). Increased 
glutamatergic tone within the medial PFC and NAcc (mesolimbic pathway) was found in 
cocaine-sensitized rats and was proposed to sustain increased DARPP-32 levels (Scheggi 
et al., 2007) associated with behavioral expression. These results shed some light onto the 
involvement of the glutamatergic system in the processing of rewarding stimuli, which 
include drugs of abuse and palatable food.  
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The excessive stimulation of glutamatergic membrane receptors has been 
implicated in a variety of neurological disorders including Alzhemier’s Disease and may 
play a role in excessive food intake. The overstimulation of NMDA receptors in 
particular leads to excitotoxicity stemming from a large intracellular influx of calcium 
(Lipton, 2005). While blocking activation of these receptors may alleviate neuronal 
injury associated with overstimulation, normal NMDA receptor function may also be 
impacted, which may lead to unwanted side effects. For example, NMDA receptor 
antagonists like ketamine, PCP, and tiletamine can lead to a state of “dissociative 
anesthesia,” where signals from parts of the brain utilizing NMDA transmission to the 
conscious mind are reduced or blocked (Tamminga et al., 1987). In addition, these drugs 
can affect other neurochemical pathways as well. Ketamine, for example, has been found 
to interact with opioid, sigma, and muscarinic receptors (Hirota and Lambert, 1996, 
Narita et al., 2001) albeit with low affinity. These systems are known to be involved in 
pain perception, cardiovascular function, and gastrointestinal motility, among other 
functions (Aroni et al., 2009). The opioid and sigma receptor systems have even been 
implicated in palatable food intake (Cottone et al., 2012; Blasio et al., 2013). Garcia et al. 
(2009) showed that repeated ketamine administration (I.P.) increased sweet food intake in 
rats while intramuscular ketamine administration was associated with reduced daily food 
intake of standard “biscuits” in certain primates (Springer and Baker, 2007).  
 Memantine has a very specific mechanism of action within the NMDA receptor 
system. As a low-affinity, open-channel blocker, it enters the ion channel preferentially 
when it is excessively open and dissociates rapidly, preventing accumulation and 
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allowing normal synaptic transmission (Lipton, 2005). By preventing NMDA receptor 
overstimulation without altering normal processes, some of the side-effects seen with 
administration of other NMDA antagonists may be avoided and it is clinically well-
tolerated (Areosa et al., 2005). Memantine, like ketamine, does affect other receptor 
systems (Danysz et al., 1997; Brau et al., 2001), but where it differs from ketamine in the 
context of our study is that it is a dopamine (D2)-receptor agonist and the potencies of 
memantine at NMDA receptors and D2 receptors are of similar orders of magnitude 
(Seeman et al., 2008). Ketamine does have some dopaminergic activity, but these effects 
are relatively weak (French and Ceci, 1990) compared to its effects on other systems. 
Decreased D2 transmission induces addictive and compulsive food-seeking behavior in 
rats with access to palatable food (Johnson and Kenny, 2010). Since dopamine-glutamate 
interactions are involved in mediating the effects of reward on behavior (Schmidt and 
Reith, 2005), memantine may utilize this relationship and is ideally suited to alleviate 
abnormal processing of rewards such as palatable food.  
We found bingeing rats consume more food in a lighted, aversive environment 
compared to chow-fed controls under vehicle conditions. Rats exposed to palatable food 
were more motivated to seek this food in an aversive area compared to the rats exposed to 
the less rewarding standard chow. This is in accordance with our hypothesis and with 
previous studies suggesting that compulsive consumption of palatable foods by obese 
individuals is done to compensate for abnormal reward processing (Wang et al., 2002). If 
a loss of control is truly associated with binge-like eating, then we expected that rats 
exposed to highly palatable food are compulsive in their eating behavior in the face of a 
 46 
negative environment. Pre-treatment with memantine (2.5 mg/kg, I.P.) attenuated this 
loss of control by reducing a rat’s compulsiveness in obtaining rewarding, palatable food. 
We used 2.5 mg/kg of memantine as we found it was the lowest effective dose that 
reduced binge-like eating. It should be noted that our interpretation of compulsive 
behavior relates strictly to its definition as reward-seeking/taking in spite of negative 
consequences (Belin et al., 2008; Davis et al., 2010; Hopf et al., 2010; Johnson and 
Kenny, 2010). Bingeing rats spent substantially more time in the aversive compartment 
where the food was located compared to the chow-fed controls. “Risk-taking” behavior is 
evident when positioned with rewarding stimuli such as cocaine, heroin, and palatable 
food high in fat and/or carbohydrates (Johnson and Kenny, 2010; Teegarden and Bale, 
2007). Pre-treatment of memantine (2.5 mg/kg, I.P.) did not significantly affect the 
difference between the 2 groups, indicating that the mechanism that drives compulsive 
and binge-like eating in the rat is distinct from the circuitry that mediates risk-taking 
behavior.  
Studies examining glutamatergic involvement in other addictive disorders such as 
cocaine dependence demonstrate that increased glutamatergic neurotransmission in the 
NAcc is important for the development of drug-seeking behavior (Di Ciano and Everitt, 
2001). Once reward-related learning is established, repeated exposure to a rewarding 
stimulus such as cocaine recruits glutamatergic transmission (Cornish and Kalivas, 2000). 
Therefore, blocking a potential target of glutamate inside of the mesolimbic pathway, 
such as the NMDA receptor, may potentially alleviate the compulsive seeking of pre-
exposed rewards. Memantine has previously indicated therapeutic potential for the 
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treatment of compulsive behavior, namely obsessive-compulsive disorder (Feusner et al., 
2009) and pathological gambling (Grant et al., 2010).  
To determine whether NMDA receptor antagonists decrease palatable food intake 
by altering the reinforcing effects of food and not through a hypothalamic mechanism, 
our study sought to confirm whether the reduction in palatable food consumption was due 
to NMDA antagonism in the NAcc, a brain area dense with the dopamine-glutamate 
interactions that mediate the effects of reward on behavior. Other studies have explored 
the effects of intra-NAcc administration of NMDA receptor antagonists on reward 
processing. Intra-NAcc injections of AP5 (competitive NMDA receptor antagonist) had 
no significant effect on food responding in rats trained in an operant conditioning model 
(Baldwin et al., 2000; Kelley et al., 1997). However, intra-NAcc injections of another 
NMDA receptor antagonist AP5 decreased both cocaine and ethanol reward (Rassnick et 
al., 1992). We found that intra-NAcc administration of memantine decreased palatable 
food intake without altering chow intake or water intake. The unique pharmacological 
properties of memantine combined with the role of the NAcc in appetitive motivation and 
positive reinforcement (Salamone, 1994) may explain these results. The glutamatergic 
and dopaminergic interactions in the NAcc and their associated signaling pathways may 
mediate hedonic responses towards food and future studies should explore these 
pathways further in order to elucidate the optimal target for pharmacological intervention 
for binge-related disorders.   
Our novel study exploring the effects of NMDA receptor antagonists on binge-
like eating behavior uses operant conditioning in order to assess reinforced-reward 
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learning. With the exception of the food deprivation aspect of the study, rats had access 
to the chow and water ad libitum at all times. This allowed us to assess eating in the 
absence of hunger in the homoeostatic context. This model is also relevant to the 
“forbidden food” hypothesis of bingeing which states that the food that people are 
restricted to, whether by someone else or on their own, is the same type of food that they 
binge on (Corwin et al., 2011b). The limited access to palatable food is important as it 
allows the assessment of “binge” eating, which has been shown to have a strong 
correlation with consuming an exorbitant amount of palatable food in short periods of 
time followed by periods of dietary restraint (Tuschi, 1990). 
  In summary, the FR1 operant paradigm mimics the binge-like consumption of 
savory foods seen in humans with binge-eating disorder. We determined that 
glutamatergic neurotransmission in the nucleus accumbens plays a critical role in binge-
like eating. Furthermore, our findings show that NMDA receptors are important 
modulators of compulsive eating behavior as memantine decreased the loss of control in 
the face of negative consequences associated with exposure to a rewarding stimulus 
(Nestler, 2004). These results indicate that manipulation of the glutamate 
neurotransmitter within the mesolimbic pathway may be a potential pharmacological 
avenue for binge-eating disorder.  
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